Klinic only prescribes branded, FDA-approved medications
As previously explained, we have calculated composites representing affective symptoms of the HAMA and HAMD and somatic symptoms of the HAMD, HAMA, and FF scores [25]
It is a GIP/GLP-1 dual agonist, engaging two incretin receptors rather than one which is why it sits in its own class relative to semaglutide, liraglutide, and dulaglutide
A potential explanation is that ESA may also be weakly utilized by other ACSL isoforms such as ACSL4, which is known to direct substrates into cholesterol esters 40
Clinical data from Epiphany treatments indicates significant results, with patients achieving up to 15% body weight reduction within three months and a 24% decrease in cardiovascular event risks
Thats a significant, heavy impact, he said